Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nocion Therapeutics Advances to Clinical Stage and Expands Leadership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalent Supports Rapid Development and Supply of Nocion Therapeutics\u2019 Clinical Trial Materials for Acute and Chronic Cough Using Blow-Fill-Seal Technology","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Arkin Bio Capital","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Nocion Therapeutics

    Menu

    Nocion Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nocion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development

              Details:

              The proceeds from the financing will be used to evaluate the lead program, NTX-1175 (taplucanium) dry powder for inhalation. It is being evaluated in Phase II clinical trial studies for the treatment of Chronic Cough.

              Lead Product(s): Taplucanium

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NTX-1175

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Arkin Bio Capital

              Deal Size: $62.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing March 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nocion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Catalent Supports Rapid Development and Supply of Nocion Therapeutics’ Clinical Trial Materials for Acute and Chronic Cough Using Blow-Fill-Seal Technology

              Details:

              NTX-1175 is being developed to treat cough and has received priority review through the U.K.’s Medicines and Healthcare products Regulatory Agency, as NOC-100 has the potential to treat both chronic and acute cough.

              Lead Product(s): NTX-1175

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NOC-100

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Catalent Pharma Solutions

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nocion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nocion Therapeutics Advances to Clinical Stage and Expands Leadership

              Details:

              First subject in a healthy volunteer Phase 1 trial of NOC-100, an inhaled formulation of NTX-1175. NTX-1175 is a novel small molecule Charged Sodium Channel Blocker (“CSCB”) being developed for cough.

              Lead Product(s): NTX-1175

              Therapeutic Area: Infections and Infectious Diseases Product Name: NOC-100

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY